已收盘 11-06 16:00:00 美东时间
+0.350
+3.45%
YDUQS Participacoes SA ( ($BR:YDUQ3) ) has issued an announcement. YDUQS’s boar...
11-04 19:25
今日重点评级关注:Rosenblatt:维持SiTime"买入"评级,目标价从750美元升至900美元;花旗:维持Madrigal Pharmaceuticals"买入"评级,目标价从725美元升至760美元
11-04 18:17
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
11-04 07:00
11月4日,Afya(AFYA)收跌0.85%,报10.55美元,成交额432.58万美元,市值9.33亿美元。 行情数据 • 开盘价:10.85美元 • 最高...
11-04 06:45
JP Morgan analyst Marcelo Santos maintains Afya (NASDAQ:AFYA) with a Overweight and lowers the price target from $19 to $17.5.
11-04 02:07
11月3日,Afya(AFYA)收涨1.82%,报10.64美元,成交额1894.23万美元,市值9.41亿美元。 行情数据 • 开盘价:10.41美元 • 最...
11-03 06:45
10月27日,Afya(AFYA)收跌29.49%,报10.64美元,成交额1893.05万美元,市值9.41亿美元。 行情数据 • 开盘价:11.71美元 ...
10-27 05:47
Regeneron has extended its agreement with BARDA to supply additional doses of Inmazeb, its Ebola treatment, through 2031, adding approximately $270 million in value. Inmazeb, the first FDA-approved Ebola treatment, has shown significant efficacy in reducing mortality. Separately, Regeneron is advancing maftivimab, a component of Inmazeb, as a potential treatment for Bundibugyo ebolavirus, with preclinical data supporting its effectiveness. The co...
10-26 11:00
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:40
今日重点评级关注:DA Davidson:维持美光科技"买入"评级,目标价从2100美元升至3000美元;Leerink Partners:维持OmniAb"跑赢大市"评级,目标价从10美元升至12美元
10-08 12:30